Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Hepatology. 2022 Oct 18;77(6):1929–1942. doi: 10.1002/hep.32693

Figure 5. AXIN1 regulates the stability of YAP/TAZ in human HCC cell lines.

Figure 5.

(A) AXIN1 and CTNNB1 mutation status in human HCC cell lines. Null, extremely low or undetectable of AXIN protein expression; Mut, mutation; Wt, wild-type. (B) Western blot analysis showing AXIN1, YAP, and TAZ levels in human HCC cell lines 0, 2, 4, 6, 12, 18, and 24 hours of CHX administration. GAPDH was used as a loading control. (C) Quantification of YAP and TAZ protein abundance in human HCC cells 0, 2, 4, 6, 12, 18, and 24 hours of CHX administration. (D) Quantification of YAP and TAZ protein abundance in EGFP or AXIN1 transfected SUN182 and SNU449 cells 0, 2, 4, 6, 12, 18, and 24 hours of CHX administration. (E) Quantification of YAP and TAZ protein abundance in scrambled siRNA (siSC) or siAXIN1 transfected HLF cells 0, 2, 4, 6, 12, 18, and 24 hours of CHX administration. (F, G) Co-immunoprecipitation assay showing AXIN1-YAP/TAZ interaction. GSK3β was used as a positive control. B-G are representative results of three independent experiments.